Filament Health Corp. (“Filament”) (NEO: FH), a natural psychedelic drug discovery and extraction technology company headquartered in Vancouver, British Columbia, completed a series of financings and its going public transaction on the NEO Exchange.
Filament’s pre-listing financings were in the aggregate amount of approximately C$12,000,000, with two concurrent financings for units and subscription receipts completing shortly prior to listing. The going public transaction was completed by way of a reverse take over of an unlisted reporting issuer led by Medalist Capital.
We acted on behalf of Filament with a team led by Jonathan Conlin (Technology and M&A) and included Sarah Gingrich, Mark Kopitar, Mark Hughes and Gabriel Lam (M&A).
Jurisdictions
- British Columbia
- Alberta
